Jump to ContentJump to Main Navigation


Open Access
* Prices subject to change. Shipping costs will be added if applicable.

See all formats and pricing

Open Access
*Prices subject to change. Shipping costs will be added if applicable.

    Natural Products against Cancer

    1 Issue per year


    VERSITA Emerging Science

    Open Access

    Natural Products Against Cancer is an international journal dedicated to publishing high quality articles in cancer research.
    It covers topics related to the anti-cancer properties of natural products, including small molecules, peptides, hormones, and anti-cancer metabolites. The journal also accepts scientific publications in the area of molecular engineering of small molecules, small molecule libraries, peptides and proteins, based on natural products, to improve the anti-cancer efficiency and/or delivery into tumor cells. Chemical, structural, cellular, and molecular approaches aimed to characterize the anti-cancer properties of these agents are major areas peer-reviewed by Natural Products Against Cancer. It publishes research articles, communications, reviews and mini-reviews, commentaries and letters to the Editor.

    Aims and Scope

    Why subscribe and read

    The first journal devoted to the emerging field of natural products against cancer; publishes high-quality, cutting-edge research on novel anti-cancer agents; promotes interactions and communication throughout the whole cancer community (scientists, patient advocates, funding agencies) around the world, to find novel treatments and to make an impact in cancer.

    Why submit

    • Open access
    • Fast-reviewing process
    • Free language editing
    • Fast and professional publishing

    Instructions for Authors

    Editorial Policy


    The journal Natural Products Against Cancer is devoted to the publication of research results in the field of natural products, including small molecules and synthetic derivatives, peptides, proteins, metabolites, possessing anti-cancer properties. The primary mission of the journal is to become the central publication venue for all members of the researcher community in Natural products against cancer. The journal is peer-reviewed, publishes in electronic-only format and on ongoing basis (no issues). The language of the journal is English.


    Manuscripts should be submitted to the Editor of the Journal, Wang Jian at jwang@versita.com.

    Manuscript submitted to this journal should: 

    • contain original work - not published elsewhere in any medium (in the whole or in part) by the authors or anyone else and not under consideration for publication in any other medium;
    • focus on the aims and scope of the journal;
    • be clearly and correctly written - should contain all essential features of a scientific publication that is easy to understand for the target audience;
    • written in English - attention to detail of the language will avoid severe misunderstandings which might lead to rejection of the paper;
    • be delivered in electronic format. 

    The journal publishes:

    • Research Articles
    • Communications and Rapid Communications
    • Reviews and Mini-Reviews
    • Commentaries
    • Letters to the Editor and Amendments 

    Formatting Requirements

    Our contributors are asked to make sure their submissions comply with rules governing the formatting. Although the journal can provide limited technical support, it is ultimately the responsibility of the author to deliver a properly formatted electronic version of the article.

    Please carefully follow the guidelines described in Instructions for Authors.

    Overview of the Editorial Process


    Each manuscript should be accompanied by a cover letter which should explicitly state that the authors have the authority to publish the work and that the manuscript (or one with substantially the same content, by any of the authors) has not been previously published in any language anywhere and that it is not under simultaneous consideration by another journal. All authors of the manuscript are responsible for its content; they must have agreed to its publication and have given the corresponding author the authority to act on their behalf in all matters pertaining to publication. The corresponding author is responsible for informing the coauthors of the manuscript status throughout the submission, review, and production process.

    Peer Review Process

    A submission may be declined by the Editor without review, if the studies reported are not sufficiently novel or important to merit publication in the journal. Manuscripts deemed unsuitable (insufficient originality or limited interest to the target audience) are returned to the author(s) without a review. The Editor may appoints an Associate Editor with expertise in the relevant field, who is fully responsible for further handling the manuscript and an ultimate decision about its acceptance/rejection.

    a) choice of reviewers

    The Editor seeks advice from experts of in the appropriate field. Research articles and communications are refereed by a minimum of two reviewers, review papers by at least three.

    b) suggestions from authors

    Authors are requested to suggest persons competent to review their manuscript. However, please note that this will be treated only as a suggestion, the final selection of reviewers is exclusively the Editor's decision. The authors’ names are revealed to the referees, but not vice versa.

    The reviewers make an objective, impartial evaluation of scientific merits of the manuscript. Reviewers operate under guidelines set forth in Guidelines for reviewers and are asked to comment on the following aspects of submitted manuscripts:

    • novelty and originality of the work;
    • broad interest to the community of researchers;
    • significance to the field, potential impact of the work, conceptual or methodological advances described;
    • study design and clarity;
    • substantial evidence supporting claims and conclusions;
    • rigorous methodology

    If a manuscript is believed to not meet the standards of the journal or is otherwise lacking in scientific rigor or contains major deficiencies, the reviewers will attempt to provide constructive criticism to assist the authors in ultimately improving their work. If a manuscript is believed to be potentially acceptable for publication but needs to be improved, it is invited for reconsideration with the expectation that the authors will fully address the reviewer’s suggestions.

    Once all reviews have been received and considered by the Editor, a decision letter to the author is drafted. There are several types of decisions possible:

    • Accept without revision
    • Minor revision
    • Major revision
    • Reject 

    Revised manuscript submission

    When revision of a manuscript is requested, authors should return the revised version of their manuscript as soon as possible. Prompt action may ensure fast publication if a paper is finally accepted for publication. If it is the first revision of an article, authors need to return their revised manuscript within 28 days. If it is the second revision authors need to return their revised manuscript within 14 days. If these deadlines are not met, and no specific arrangements for completion have been made with the Editor, the manuscript will be treated as a new one and will receive a new identification code along with a new registration date.

    Final decision is made by the Editor.

    Final proofreading

    Authors will receive a pdf file with the edited version of their manuscript for final proofreading. This is the last opportunity to view an article before its publication on the journal web site. No changes or modifications can be introduced once it is published. Thus authors are requested to check their proof pages carefully against manuscript within 3 working days and prepare a separate document containing all changes that should be introduced. Authors are sometimes asked to provide additional comments and explanations in response to remarks and queries from the language or technical editors.

    Immediate publication

    Because the journal has no issues, manuscripts accepted for publication are immediately published online (that is when final proofreading is performed by authors, and all concerns are resolved). Once a manuscript appears on the Web site it is considered as published.


    Because the journal is published in Open Access model, and has no printed version, the authors receive no reprints.


    If any errors are detected in the published material, they should be reported to the Editor. The corresponding authors should send appropriate corrected material to the Editor via email. This material will be considered for publication as soon as feasible.


    All authors retain copyright, unless – due to their local circumstances – their work is not copyrighted. The non-commercial use of each article will be governed by the Creative Commons Attribution-NonCommercial-NoDerivs license. The corresponding author grants Versita the exclusive license to commercial use of the article, by signing the License to Publish. Scanned copy of license should be sent by e-mail to the Editor of the journal, as soon as possible.

    Scientific misconduct and other fraud

    Scientific misconduct is defined by the Office of Research Integrity as "fabrication, falsification, plagiarism, or other practices that seriously deviate from those that are commonly accepted within the academic community for proposing, conducting, or reporting research". In cases where there is a suspicion or allegation of scientific misconduct or fraudulent research in manuscripts submitted or published, the Editors reserve the right to impose sanctions on the authors, such as:

    • an immediate rejection of the manuscript;
    • banning author(s) from submitting manuscripts to the journal for a certain period of time;
    • retracting the manuscript;
    • alerting editors of other journals and publishers;
    • bringing the concerns to the authors' sponsoring or funding institution or other appropriate authority for investigation 

    This journal publishes only original manuscripts that are not also published or going to be published elsewhere. Multiple submissions/publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If they are detected only after publication, the journal reserves the right to publish a Retraction Note.

    Retraction Policy

    Serious errors in a published manuscript and infringements of professional ethical codes will result in an article being retracted. This will occur where the article is clearly defamatory, or infringes others' legal rights, or where the article is, or there is good reason to expect it will be, the subject of a court order, or where the article, if acted upon, might pose a serious health risk. In any of these cases all coauthors will be informed about a retraction. A Retraction Note detailing the reason for retraction will be linked to the original article.

    Use of experimental animals and human subjects

    Submission of a manuscript to this journal implies that any experimental research that is reported in the manuscript has been performed with the approval of an appropriate ethics committee. Manuscripts may be rejected if the Editor considers that the research has not been carried out within an ethical framework. Research involving human participants must be in compliance with the Helsinki Declaration, and any experimental research on animals must follow internationally recognized guidelines. A statement to this effect must appear in the Experimental Procedures section of the manuscript, including the name of the body which gave approval, with a reference number where appropriate. No identifying information should be published for human subjects unless the information is essential for scientific purposes and the patient gives written Informed Consent for publication. Information about Informed Consent obtained from participants should be indicated in the published article. We encourage authors to submit a sample of a patient consent form, and may require submission on particular occasions.

    See Instructions for Authors for further details.

    Conflicts of Interest

    In order to encourage transparency without impeding publication, all authors, referees and editors must declare any association that poses a conflict of interest in connection with the manuscript. There should be no contractual relations or proprietary considerations that would affect the publication of information contained in a submitted manuscript. A competing interest for a scholarly journal is anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, review, or publication of research findings, or of articles that comment on or review research findings. Potential conflicts of interest exist when an author, editor or reviewer has financial, personal or professional interests in a publication that might influence their scientific judgment.

    Examples of such conflicts include, but are not limited to:

    • Financial conflicts: stock ownership; patents; paid employment or consultancy; board membership; research grants; travel grants and honoraria for speaking or participation at meetings; gifts
    • Personal conflicts: relationship with editors, editorial board members, or with possible reviewers who have had recent or ongoing collaborations with the authors, have commented on drafts of the manuscript, are in direct competition, have a history of dispute with the authors
    • Professional conflicts: public associations with institutions or corporations whose products or services are related to the subject matter of the article; membership of a government advisory council/committee; relationship with organizations and funding bodies 

    Authors should declare whether they have any conflicts of interests that could have influenced the reporting of the experimental data or conclusions in their paper. Such a statement should list all potential interests or, if appropriate, should clearly state that there are none. The editors may decide not to publish papers when we believe the competing interests are such that they may have compromised the work or the analyses or interpretations presented. Upon submission of a manuscript, authors may suggest to exclude any specific editors or reviewers from the peer review of their article. It is the responsibility of authors to disclose in the Acknowledgments section any funding sources for the project or other relationships that are relevant.

    Editors should consider whether any of the above competing interests are relevant to them and the manuscript under consideration. Editor who believes that the conflict will preclude an impaired judgment should disclose to the Editor the nature of the conflict and decline to handle the paper.

    Reviewers should consider whether any of the above applies to them and declare any such competing interests. If they feel they cannot review a paper because of any competing interest, they should tell us. They should also declare any association with the authors of a paper.

    Submission to Natural Products Against Cancer

    Please submit your manuscripts to Natural Products Against Cancer via email to

    Jian Wang

    Dejan Nikolić

    Journal Editor
    Wang Jian, National University of Singapore, Singapore

    Associate Editor
    Dejan Nikolić, University of Illinois at Chicago, USA

    Editorial Advisory Board
    Esperanza J. Carcache de Blanco, The Ohio State University, USA
    Joanna Burdette, University of Illinois at Chicago, USA
    David Yu-kai Chen, Seoul National University, South Korea
    Shunsuke Chiba, Nanyang Technological University, Singapore
    Mauricio Cuello, Universidad Pontificia Catolica de Chile, Chile
    Muriel Cuendet, School of pharmaceutical sciences, Université de Genève, Switzerland 
    Wei-min Dai, The Hong Kong University of Science and Technology, Hong Kong
    Aimee L. Eggler, Villanova University, USA
    Daniel Fabricant, Division of Dietary Supplement Programs, Food and Drug Administration, College Park, USA
    Stefan Gafner, Tom's of Maine, USA
    Peter Hatmann, The University of Western Australia, Australia
    Arne Heyerick, Reliable Cancer Therapies, Verbier, Switzerland
    Xuelong Hou, Shanghai Institute of Organic Chemistry, China
    Richard Hsung, School of Pharmacy,University of Wisconsin-Madison, USA
    Kuowei Huang, King Abdullah University of Science and Technology, Saudi Arabia
    Ning Jiao, School of Pharmacy, Peking University, China
    Dmitri Kireev, The University of North Carolina, USA
    Fuk Yee Kwong, The Hong Kong Polytechnic University, Hong Kong
    Aiwen Lei, Wuhan University, China
    Guangxin Liang, Nankai University, China
    Guigen Li, Texas Tech University, USA
    Lei Liu, Tsinghua University, China
    Rihe Liu, The University of North Carolina, USA
    Paul M Lizardi, Yale University, USA
    George O'Doherty, Northeastern University, USA
    Silvana Petrović, College of Pharmacy, University of Belgrade, Serbia
    Yian Shi, Colorado State University, USA
    Zhangjie Shi, Peking University, China
    Tibor Soós, Hungarian Academy of Sciences, Hungary
    Fred Stevens, Oregon State University, USA
    Jianwei Sun, The Hong Kong University of Science and Technology, Hong Kong
    Rongbiao Tong, The Hong Kong University of Science and Technology, Hong Kong
    Meixiang Wang, Tsinghua University, China
    Wei Wang, University of New Mexico, USA
    Xu Wu, Harvard Medical School, Harvard University, USA
    Zhen Yang, Peking University, China
    Xinshan Ye, School of Pharmacy, Peking University, China
    Shuli You, Shanghai Institute of Organic Chemistry, China
    Biao Yu, Shanghai Institute of Organic Chemistry, China
    Xumu Zhang, Rutgers, The State University of New Jersey, USA
    Jing Zhao, Shenzhen Graduate School of Peking University, China

    Assistant Editors
    Xuefeng Jiang, East China Normal University, China

    Jian Wang

    Dejan Nikolic

    Versita Ltd.
    ul. Bogumiła Zuga 32A
    01-811 Warsaw, Poland
    Phone: +48 22 701 50 15

    Please log in or register to comment.